Eli Lilly and Company has become a key player in the production of tirzepatide, a groundbreaking drug for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, exhibits significant capacity to improve glycemic control and reduce cardiovascular risks. The sophisticated synthesis of tirzepatide requires a series of carefully controlled